Out to ‘re­think the drug de­sign process,’ AI star Daphne Koller is cre­at­ing a new ma­chine learn­ing ven­ture at in­sitro with some heavy­weight back­ers

Daphne Koller has been busy.

Just two months since the high pro­file AI ex­pert ex­it­ed Google’s an­ti-ag­ing biotech Cal­i­co Labs, where she was chief com­put­ing of­fi­cer, Koller has gath­ered a group of mar­quee in­vestors to back a tech up­start — in­sitro — with plans to de­vel­op a ma­chine learn­ing plat­form equipped with cus­tom-built datasets to cre­ate a new and far more ef­fi­cient ap­proach to drug dis­cov­ery and de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.